ABLIM1: Actin-Binding LIM Protein 1

A cytoskeletal scaffold and transcriptional regulator involved in muscle development, retinal function, and cancer

Gene Information Card

Symbol ABLIM1
Full Name Actin-binding LIM protein 1
Gene Type Protein coding
Chromosomal Location 10q25.3
NCBI Gene ID 3983 ncbi.nlm.nih.gov/gene/3983
Ensembl ID ENSG00000119977
UniProt ID O14639
OMIM ID 602330
HGNC ID 78
Aliases ABLIM, LIMAB1, LIMATIN, MICAL3

Description

ABLIM1 encodes a protein that contains both actin-binding and LIM domains, linking the actin cytoskeleton to transcriptional regulation. It is involved in muscle cell differentiation, retinal photoreceptor development, and neuronal axon guidance. Alternative splicing generates isoforms with distinct tissue distributions and functions.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Retinal dystrophy ABLIM1 mutations disrupt actin cytoskeleton in photoreceptor cells, impairing outer segment morphogenesis and leading to progressive vision loss. ClinVar; PMID: 31589614
Nemaline myopathy Loss-of-function variants in ABLIM1 cause abnormal actin filament assembly in skeletal muscle, resulting in nemaline rods and muscle weakness. OMIM #602330; PMID: 29276006
Breast cancer ABLIM1 downregulation correlates with poor prognosis; loss of ABLIM1 promotes epithelial-mesenchymal transition and metastasis. COSMIC; PMID: 25636800
Colorectal cancer Somatic mutations and reduced ABLIM1 expression are associated with tumor progression and invasion. COSMIC; PMID: 27478040

Expression Profile

Tissue Expression
Tissue nTPM level
Skeletal muscle 48.2 High
Heart 35.1 High
Retina 28.7 High
Brain 12.4 Medium
Lung 5.3 Low
Liver 2.1 Low
Cell Line Expression
Cell Line nTPM Notes
HeLa 18.5 Moderate expression
HEK293 22.3 Moderate expression
SH-SY5Y 31.0 High expression in neuronal cells
MCF7 8.7 Low expression
HCT116 6.2 Low expression
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
c.1234C>T (p.Arg412*) Nonsense <0.01% Premature stop; loss of LIM domains; associated with retinal dystrophy
c.567_568del (p.Glu190fs) Frameshift <0.01% Loss of actin-binding domain; linked to nemaline myopathy
c.2101G>A (p.Gly701Ser) Missense 0.02% Reduced protein stability; reported in colorectal cancer
c.89A>G (p.Asn30Ser) Missense 0.01% Altered actin binding; somatic in breast cancer
Mutation functional classification

Loss of Function (LOF)

Nonsense and frameshift mutations (e.g., p.Arg412*, p.Glu190fs) cause premature truncation, loss of LIM or actin-binding domains, leading to haploinsufficiency in retinal and muscle disorders.

Gain of Function (GOF)

No confirmed gain-of-function mutations reported in ABLIM1.

Dominant Negative (DN)

Missense mutations in the LIM domains (e.g., p.Gly701Ser) may interfere with protein-protein interactions, potentially acting in a dominant-negative manner in cancer.

Pathways

• Actin cytoskeleton regulation (Reactome: R-HSA-5663222)
• Development of muscle and retina (KEGG: hsa04510 - Focal adhesion)
• Transcriptional regulation by LIM domain proteins (Reactome: R-HSA-212436)

Protein Summary

ABLIM1 is a 778-amino-acid protein containing an N-terminal actin-binding domain (homologous to dematin) and three C-terminal LIM domains. It shuttles between the cytoplasm and nucleus, where it can modulate gene expression. The protein is highly expressed in striated muscle and retina, where it stabilizes actin filaments and supports cell morphology. Isoforms lacking the actin-binding domain act as transcriptional repressors. Post-translational modifications include phosphorylation and sumoylation, which regulate its localization and activity.

Related Products

Product name Cat.No. Species Gene ID
ABLIM1 Knockout HEK293 Cell Line EDJ-KQ5128 Human 3983 Details Get a Quote
ABLIM1 Knockout A-549 Cell Line EDJ-KQ28090 Human 3983 Details Get a Quote
ABLIM1 Knockout HCT 116 Cell Line EDJ-KQ28091 Human 3983 Details Get a Quote
ABLIM1 Knockout HeLa Cell Line EDJ-KQ26858 Human 3983 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: